PPARγ is key in NAFLD development, affecting lipid buildup, insulin resistance, inflammation, oxidative and ER stress, and fibrosis, making it a potential treatment target (Chen et al. 2023; Qiu et al. 2023). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.